Spoken Alpha
Celldex Therapeutics, Inc.
Celldex Therapeutics develops monoclonal and bispecific antibodies designed to treat severe inflammatory, allergic, and autoimmune diseases by targeting mast cell biology.
Celldex Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $3.02B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CLDX.
$ curl https://api.spokenalpha.com/v1/companies/CLDXFAQ
Spoken Alpha indexes CLDX's earnings call transcripts at https://spokenalpha.com/companies/CLDX. Each call links to attributed speakers and parsed analyst Q&A. Celldex Therapeutics, Inc.'s own investor relations page is at https://ir.celldex.com/.
Celldex Therapeutics, Inc. (CLDX) held its most recent earnings call on 2022-02-28, covering fiscal Q4 2021.
Celldex Therapeutics, Inc. (CLDX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-1.02 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.94 | $-1.04 | +9.6% | $22.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-1.18 | $-1.13 | -4.4% | $15.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-01 | $-1.22 | $-1.00 | -22.0% | $75.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-1.01 | $-0.89 | -13.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.85 | $-0.86 | +1.2% | $730.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.81 | $-0.74 | -9.5% | $695.0K | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $-0.71 | $-0.71 | +0.6% | $1.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.64 | $-0.67 | +4.5% | $3.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.54 | $-0.59 | +8.5% | $2.5M | — | — | EODHD |
| Q1 FY2024 | 2024-05-05 | $-0.56 | $-0.67 | +16.4% | $156.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-25 | $-0.83 | $-0.74 | -12.2% | $4.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.81 | $-0.66 | -22.7% | $1.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.65 | $-0.66 | +1.5% | $268.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.62 | $-0.60 | -3.3% | $967.0K | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.56 | $-0.59 | +5.1% | $1.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.57 | $-0.57 | 0.0% | $407.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.58 | $-0.42 | -38.1% | $163.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.50 | $-0.43 | -16.3% | $174.0K | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.43 | $-0.42 | -2.4% | $334.0K | — | — | EODHD |
Source: EODHD. CLDX reported actuals as published; sparse fields render as —.